- Home
- SRBK vs TLSA Comparison
SRBK vs TLSA Comparison
Compare SRBK & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRBK | TLSA |
|---|---|---|
| Founded | 1887 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.1M | 145.1M |
| IPO Year | 2023 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SRBK | TLSA |
|---|---|---|
| Price | $18.87 | $0.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.98 |
| AVG Volume (30 Days) | 28.2K | ★ 509.7K |
| Earning Date | 10-26-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $43.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.60 | $0.57 |
| 52 Week High | $20.95 | $1.90 |
Technical Indicators
Market Signals| Indicator | SRBK | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 33.00 |
| Support Level | $18.57 | $0.57 |
| Resistance Level | $19.95 | $1.21 |
| Average True Range (ATR) | 0.49 | 0.08 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 23.86 | 17.65 |
Price Performance
Historical ComparisonAbout SRBK SR Bancorp Inc.
SR Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers a variety of deposit and loan products to individuals and small businesses, the majority of which are located in its primary market area.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.